Neuroprotective Peptides Inhibit MAPK3 to Enhance Memory
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders such as Parkinson's, Alzheimer's, and Huntington's Diseases are inadequate in addressing cognitive decline and neuronal death, with existing methods failing to effectively enhance memory and prevent neurodegeneration.
Innovation Solution
Development of peptides derived from the N-terminal domain of ERK1 that inhibit MAPK3 protein kinase, facilitating selective activation of nuclear ERK signalling, promoting ERK-mediated gene transcription and chromatin remodelling, and enhancing memory consolidation and neuronal survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical inhibitors of MEK kinases are used to activate ERK signalling, then memory consolidation is enhanced, but cognitive enhancement and neuroprotection remain unproven and memory deficits occur in learning tasks
Solution Approach 1:
The patent uses a cell-penetrating peptide (CPP) as an intermediary delivery system to transport the ERK1-derived peptide across the blood-brain barrier and into neuronal cells. This mediator enables the active peptide to reach its target without causing the harmful side effects associated with chemical MEK inhibitors, thereby enhancing memory consolidation while avoiding cognitive deficits
Solution Approach 2:
The invention changes the molecular parameters by using a specific peptide sequence derived from the N-terminal domain of ERK1 (amino acids 1-35) instead of chemical MEK inhibitors. This parameter change - from chemical compounds to a biologically derived peptide - maintains the ability to enhance memory consolidation while eliminating the harmful side effects of cognitive impairment and memory deficits
2Reliability
If ERK signalling is activated to promote neuronal survival, then neuroprotection is achieved, but conflicting evidence exists regarding pro-apoptotic effects
Solution Approach 1:
The patent applies local quality by targeting ERK2 specifically in the nucleus of neuronal cells, rather than activating ERK signalling systemically throughout the cell. The peptide specifically promotes nuclear translocation of ERK2 and activates nuclear ERK-dependent signalling pathways, which are known to promote neuronal survival without triggering pro-apoptotic effects that may occur with broader ERK activation
Solution Approach 2:
The cell-penetrating peptide acts as an intermediary that selectively delivers the ERK1-derived peptide into neuronal cells and facilitates its nuclear translocation. This intermediary ensures that the neuroprotective effects are localized to the nucleus where they promote survival without activating cytoplasmic pathways that could lead to apoptosis
3Ease of operation
If existing treatments are used for neurodegenerative disorders, then some symptomatic relief is achieved, but cognitive decline and neuronal death are not effectively prevented
Solution Approach 1:
The patent employs preliminary action by administering the ERK-activating peptide before neurodegenerative changes fully manifest or progress. The peptide proactively enhances ERK signalling to prevent neuronal death and cognitive decline before they occur, rather than merely treating symptoms after damage has already happened. This preventive approach addresses the unmet need for treatments that can stop neurodegeneration in its tracks
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides improve memory acquisition and formation, prevent neurodegeneration, and offer cognitive enhancement in both healthy individuals and those with neurodegenerative disorders, representing a potential therapy for major brain disorders with unmet medical needs.
Implementation Method 1
peptides derived from the N-terminal domain of ERK1 that inhibit MAPK3 protein kinase, facilitating selective activation of nuclear ERK signalling
Data Source
AI summary
Inhibitors of MAPK3 (ERK1 MAP kinase), in particular to polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents, are disclosed. Related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway, are also disclosed. Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed.